+2.87% gained 5.1% in premarket trading on Friday after it shared details from a late-stage clinical trial evaluating its experimental drug pegcetacoplan against Alexion Pharmaceuticals Inc.'sThe study found that pegcetacoplan was better than Soliris in improving hemoglobin levels in adults with the rare blood disease.